ABCL (AbCellera Biologics) Moat Score: 6/10 (As of Jun. 27, 2026)


ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $7.38
GF Value $5.62
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics Moat Score?

AbCellera Biologics ABCL +10.81% 59 Moat Score is 6 as of Jun. 27, 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,404 Biotechnology companies, AbCellera Biologics ranks better than 98.93% on this metric.

AbCellera Biologics has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

AbCellera Biologics has Narrow Moat: AbCellera Biologics Inc has a strong narrow moat due to its valuable intellectual property and significant R&D capabilities in biotechnology. The company benefits from customer loyalty and some pricing power, but faces competition that limits its market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AbCellera Biologics might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

AbCellera Biologics  (NAS:ABCL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AbCellera Biologics Moat Score Related Terms

ABCL vs SRPT, RAPP, RXRX: Moat Score Comparison

For the Biotechnology subindustry, AbCellera Biologics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Moat Score distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Moat Score falls into.


ABCL
59GF Score
AbCellera Biologics Inc ABCL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
AbCellera Biologics (ABCL) has a Moat Score of 6 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, AbCellera Biologics ranks #15 out of 1404 companies in the Biotechnology industry, placing it in the top 1.1%.
Is AbCellera Biologics' Moat Score too high?
AbCellera Biologics' current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. AbCellera Biologics' value of 6 is 200% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #15 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Moat Score compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #15 out of 1404 companies for Moat Score. This places AbCellera Biologics in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. AbCellera Biologics' value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Moat Score is 6 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • Moat Score: 6
  • GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
  • GF Score™: 59/100 with 5 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1404)

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.38
Price
$5.62
GF Value